Search Results - Cardiovascular%2c+Renal%2c+%26+Metabolism

7 Results Sort By:
Cofilin inhibitor for the treatment of hemorrhagic brain injury-induced inflammation
Project ID D2019-35 Background Cofilin regulates actin filament assembly and organization in most cells, including during macrophage, T-cell, and dendritic activation and migration. Over-activation of cofilin can lead to microglia inflammation in the brain. Although Cofilin has been shown to be involved in the secondary injury of intracerebral hemorrhage...
CAR T Preventive/Therapeutic approach for Type 1 Diabetes
Project ID: D2019-07Background Type 1 diabetes (T1D) is an autoimmune disease with no cure and is currently treated with daily insulin injections. Cytotoxic T cells have been shown to contribute to the progression of the disease, and can be down regulated to control the attack on insulin-producing beta cells. Regulatory T cells (Tregs) have been investigated...
PEGylated Bilirubin for the treatment of Hyperlipidemia, Obesity, and Type II Diabetes
Project ID: D2018-40Background:Obesity, a low-grade inflammatory disease, has affected more than 150 million people in the US. Obesity and its associated risk factors are a prelude to the development of type II diabetes that accounts for a vast majority of the 25.8 million diabetes cases in the US. Bilirubin, a yellow pigment produced during red blood...
Spontaneous Type I Diabetes Mouse Model
Project ID: D2015-60Background Although the NOD mouse is the current standard for studies of type I diabetes (T1D), no curative therapies resulting from this model have passed clinical trials. Knock in/out models cannot be used to mimic the total pathophysiology of diabetes. In order to develop a cure for T1D, there is a need for an animal model of...
Use of Small Molecule Inhibitors as Anti-Thrombotic Agents
Project: D2016-03IP Status: PCT filed Invention Description: Discovery of a new family of small molecules that can be used to decrease the risk of thrombosis in patients with several diseases. Novelty: The most important aspect of this new antithrombotic is that it prevents the transition of platelets to a hypersensitive state without impacting normal...
“Thin” Molecules for Treating Obesity and Type II Diabetes
Project ID: D2016-29IP Status: PCT patent application filedInvention Description and Novelty: “Thin” molecules offer stronger binding to PPAR and include greater lipid burning and glucose lowering properties. Applications: Dyslipidemia, obesity and type II diabetes Value propositions: • Bilirubin reduces body fat percentage and...
Generation of Stable iTregs as Therapeutics against Autoimmune Diseases (Type I Diabetes)
Project ID: D2010-30 Invention novelty: New methods for induction and expansion of stable iTregs without addition of exogenous TGF-βValue Proposition: The “anti-self” immune response in human body leads to development of autoimmune diseases. For example, Diabetes mellitus type 1 (formerly known as juvenile diabetes) results from autoimmune...